
Management of Relapse or Refractory Patients
Patients who relapse from AML17, can be entered into the treatment arm for high risk patients in AML19.
Key Questions for relapse/refractory patients:
- Is the patient refractory, i.e., has never achieved remission?
If remission was obtained:
- Has the relapse occurred through treatment or after treatment was completed?
- If so, what is the interval between the end of treatment and the relapse?
- Is further chemotherapy indicated?
- Is allo-BMT a possibility? Either Sib or MUD, standard or non myeloblative.
What does the patient want?
These considerations will dictate management and vary from patient to patient.
Check to see if there is a relapse/refractory trial to offer the patient. See the Clinical Trials page on the Intranet or phone the Clinical Trials Co-ordinator (ext: 80377).
Topic Code: 4291